indoramin hydrochloride: clinical use

Prescribing considerations

• Control incipient cardiac failure before considering treatment.
• Use caution with hepatic or renal impairment and in older people because clearance may be reduced.
• Use great caution in epilepsy and assess carefully in Parkinson's disease or a history of depression.
• Warn about early drowsiness, postural hypotension, driving impairment and additive effects from alcohol or sedatives.
• Ensure the ophthalmic surgeon knows about current or previous alpha-1 blocker exposure before cataract surgery.

Contraindications and cautions

• Hypersensitivity to indoramin or any excipient
• Established heart failure
• Concurrent monoamine oxidase inhibitor treatment
• Relevant hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption because the selected formulation contains lactose

Monitoring

• Blood pressure, including postural symptoms and syncope risk
• Drowsiness and functional impairment after initiation or treatment changes
• Clinical response of urinary symptoms and flow
• Mood, extrapyramidal symptoms and seizure risk where relevant
• Tolerability in renal or hepatic impairment and older people

Clinical pharmacology

A selective, competitive postsynaptic alpha-1 adrenoceptor antagonist that reduces peripheral vascular resistance and relaxes hyperplastic prostatic smooth muscle. It is rapidly absorbed, highly protein-bound and undergoes extensive first-pass metabolism; the reported elimination half-life is about five hours.

Formulation and product differences

• The selected product is a pale-yellow, triangular film-coated tablet with a raised kite shape on each face.
• It contains lactose monohydrate and is supplied in blister packaging.

Tablet

Route: Oral

Strengths: 20 mg